Medicus Pharma Appoints Carolyn Bonner as CFO While Advancing Multiple Clinical Programs
核心洞察
Medicus Pharma (搜索) has appointed Carolyn Bonner as Chief Financial Officer in addition to her role as President, following the resignation of co-founder Jim Quinlan for health reasons.
The company's SkinJect (搜索) program for basal cell carcinoma (搜索) treatment using doxorubicin microneedle arrays showed over 60% clinical clearance in interim Phase 2 analysis and received FDA support for 505(b)(2) regulatory pathway.
Medicus expanded its pipeline through the acquisition of Antev Limited (搜索), adding Teverelix, a GnRH antagonist for cardiovascular high-risk prostate cancer (搜索) patients with FDA-approved Phase 2b study designs.
Medicus Pharma (搜索) Ltd. (NASDAQ: MDCX) announced the appointment of Carolyn Bonner as Chief Financial Officer, effective immediately, while the precision-guided biotech company continues to advance multiple clinical development programs across its expanding therapeutic pipeline.
Bonner, who has served as President since joining the company and as Acting CFO since September 12, 2025, assumes the dual role following the formal resignation of co-founder Jim Quinlan for health reasons. "Carolyn has been providing strong financial leadership since stepping in as acting CFO in September," stated Dr. Raza Bokhari, Medicus's Executive Chairman & CEO. "Her appointment as CFO, in addition to President, enhances continuity, ensures stability and brings further alignment in our corporate objectives."
Leadership Transition and Experience
Bonner brings nearly 20 years of experience in the healthcare and life sciences sector, with expertise spanning executive leadership, corporate development, operations, and capital markets engagement. Before joining Medicus, she served as President & Chief Executive Officer of PCL, Inc., a CAP-accredited specialty laboratory with operations in the United States and United Arab Emirates. Her previous roles included business development positions at Rosetta Genomics Ltd., a NASDAQ-listed molecular diagnostics company, and Inform Diagnostics, Inc.
In her expanded role, Bonner will oversee financial reporting and controls, capital markets strategy, budgeting and forecasting, and treasury operations, while continuing to lead strategic planning and cross-functional coordination across clinical and corporate development initiatives.
SkinJect Clinical Progress Shows Promise
The company's flagship SkinJect (搜索) program continues to demonstrate clinical progress in treating basal cell carcinoma (搜索) (BCC) through its novel doxorubicin-containing microneedle arrays (D-MNA). The ongoing Phase 2 clinical study SKNJCT-003, conducted across nine clinical sites in the United States, is a double-blinded, placebo-controlled triple-arm proof-of-concept study designed to non-invasively treat BCC of the skin.
In March 2025, Medicus announced a positively trending interim analysis for SKNJCT-003 demonstrating more than 60% clinical clearance. The interim analysis was conducted after more than 50% of the then-targeted 60 patients in the study were randomized, though the company noted that these preliminary findings may or may not correlate with the final study results.
The program received significant regulatory support in September 2025 when the FDA provided positive feedback during a Type C meeting, indicating that the company may follow the FDA's 505(b)(2) regulatory pathway for the non-invasive treatment of BCC using dissolvable D-MNA.
International Expansion and Regulatory Approvals
Medicus has successfully expanded its clinical operations internationally. In October 2025, the company treated its first patient in the SKNJCT-004 clinical study in the United Arab Emirates, which is expected to randomize 36 patients across six sites with Cleveland Clinic Abu Dhabi serving as the principal investigator.
The company received full regulatory and ethical approvals in the United Kingdom in November 2025 to expand the ongoing Phase 2 clinical study SKNJCT-003. The approvals were issued by the Medicines and Healthcare products Regulatory Agency (MHRA), the Health Research Authority (HRA), and the Wales Research Ethics Committee (WREC) following comprehensive scientific review and confirmation of compliance with UK Good Clinical Practice standards.
Pipeline Expansion Through Strategic Acquisition
In August 2025, Medicus completed the acquisition of Antev Limited (搜索), a UK-based late clinical stage biotech company developing Teverelix, a next-generation GnRH antagonist. Teverelix trifluoroacetate is a long-acting gonadotrophin-releasing hormone antagonist designed as a first-in-market product for cardiovascular high-risk advanced prostate cancer (搜索) patients and patients with first acute urinary retention (搜索) relapse episodes due to enlarged prostate.
Unlike GnRH agonists, which can cause an initial surge in testosterone levels, Teverelix directly suppresses sex hormone production without this surge, potentially reducing cardiovascular risks. The drug is formulated as a microcrystalline suspension, allowing for sustained release and a six-week dosing interval, which may improve patient compliance and outcomes.
Teverelix has demonstrated clinical progress through multiple phases of development. In September 2020, Antev completed a Phase 1 clinical trial in 48 healthy male volunteers, where Teverelix was shown to be well tolerated with no dose-limiting toxicities and demonstrated rapid testosterone suppression. A Phase 2a study completed in February 2023 in 50 patients with advanced prostate cancer (搜索) achieved the primary endpoint of greater than 90% probability of castration levels of testosterone suppression (97.5%), though the secondary endpoint of maintaining this rate above 90% was not met, with the probability dropping to 82.5% by Day 42.
The FDA has provided regulatory guidance for Teverelix development, approving Phase 2b study designs in December 2023 for advanced prostate cancer (搜索) covering 40 patients and in November 2024 for acute urinary retention (搜索) covering 390 patients.
Patient Access Initiative for Rare Disease
In October 2025, Medicus announced a strategic collaboration with the Gorlin Syndrome Alliance (搜索) (GSA) to advance compassionate access to SkinJect (搜索) for patients suffering from Gorlin Syndrome (搜索), also known as nevoid basal cell carcinoma (搜索) syndrome. Under this collaboration, Medicus and the GSA will jointly pursue the Expanded Access IND Program with the FDA to allow patients with multiple, recurrent, or inoperable BCCs to access SkinJect under physician-supervised treatment protocols.
The initiative aims to establish a framework for expanded access while collecting valuable real-world safety and tolerability data to inform future regulatory filings. It will also integrate patient community-led insights and data into the design, monitoring, and long-term development of SkinJect (搜索) in this rare disease population.
Strategic Partnerships and Future Development
The company has also entered into a non-binding memorandum of understanding with Helix Nanotechnologies (搜索), Inc., a Boston-based biotech company focused on developing a proprietary advanced mRNA platform, to explore co-development of thermostable infectious disease vaccines. This partnership represents potential expansion of Medicus's microneedle delivery platform into vaccine applications.